Cross-source evidence timeline
Dasiglucagon research timeline
Follow 20 selected, directly cited source records from April 21, 2017 through November 9, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Literature metadata
Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting.↗
PubMed lists PMID 33906916 in Diabetes care as Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-04-27 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 27, 2021 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Dasiglucagon Hydrochloride.↗
PubMed lists PMID 33998648 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2021-07-22 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 22, 2021 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03941236↗
PeptideScanner retained ClinicalTrials.gov record NCT03941236 at 2026-11-16T01:42:39.027Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026
Source year
2025
Clinical trials
ClinicalTrials.gov record NCT05378672↗
PeptideScanner retained ClinicalTrials.gov record NCT05378672 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-07-20, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04172441↗
PeptideScanner retained ClinicalTrials.gov record NCT04172441 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-03-14, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026
Source year
2023
Clinical trials
ClinicalTrials.gov record NCT03777176↗
PeptideScanner retained ClinicalTrials.gov record NCT03777176 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-12-13, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026Regulatory
Federal Register notice 2023-26260↗
The Federal Register published notice 2023-26260, attributed to FDA and its parent HHS department, on 2023-11-30. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dasiglucagon.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03895697↗
PeptideScanner retained ClinicalTrials.gov record NCT03895697 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04836273↗
PeptideScanner retained ClinicalTrials.gov record NCT04836273 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-02, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026
Source year
2022
Clinical trials
ClinicalTrials.gov record NCT04764968↗
PeptideScanner retained ClinicalTrials.gov record NCT04764968 at 2026-11-16T01:42:39.027Z. Its registry update date was 2022-09-07, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026
Source year
2021
Clinical trials
ClinicalTrials.gov record NCT03667053↗
PeptideScanner retained ClinicalTrials.gov record NCT03667053 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03378635↗
PeptideScanner retained ClinicalTrials.gov record NCT03378635 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03688711↗
PeptideScanner retained ClinicalTrials.gov record NCT03688711 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-19, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03216226↗
PeptideScanner retained ClinicalTrials.gov record NCT03216226 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-04, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03735225↗
PeptideScanner retained ClinicalTrials.gov record NCT03735225 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-03-23, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026Regulatory
Drugs@FDA application NDA214231↗
The official Drugs@FDA dataset lists original submission 1 for NDA 214231 with status AP dated 2021-03-22, and names dasiglucagon hydrochloride among the application record's active ingredients.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04449692↗
PeptideScanner retained ClinicalTrials.gov record NCT04449692 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026
Source year
2020
Clinical trials
ClinicalTrials.gov record NCT03984370↗
PeptideScanner retained ClinicalTrials.gov record NCT03984370 at 2026-11-16T01:42:39.027Z. Its registry update date was 2020-03-31, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026
Source year
2019
Clinical trials
ClinicalTrials.gov record NCT03840278↗
PeptideScanner retained ClinicalTrials.gov record NCT03840278 at 2026-11-16T01:42:39.027Z. Its registry update date was 2019-12-16, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026
Source year
2017
Clinical trials
ClinicalTrials.gov record NCT02916251↗
PeptideScanner retained ClinicalTrials.gov record NCT02916251 at 2026-11-16T01:42:39.027Z. Its registry update date was 2017-04-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Added to PeptideScanner November 16, 2026